Natera's Signatera Shows Strong Prognostic Value in Largest Lung Cancer MRD Study — Natera, Inc.

Event summary

Natera presented data from the largest molecular residual disease (MRD) study in lung cancer, involving 1,129 patients with resected stage 1-3 non-small cell lung cancer (NSCLC).
Signatera MRD detection in the early post-surgical window (7–90 days after surgery) was strongly prognostic of recurrence-free survival, with Signatera-negative patients showing a 25% higher absolute 3-year RFS.
Signatera-positive patients had approximately 5X the risk of recurrence or death during surveillance.
Findings were consistent across both the primary surgical and perioperative cohorts, supporting broad applicability of Signatera monitoring across resected stage 1-3 NSCLC.

The big picture

Natera's data underscores the growing role of MRD detection in precision oncology, particularly in lung cancer where recurrence risk is high. The study's scale and consistent findings across cohorts position Signatera as a potential standard in post-surgical monitoring, aligning with broader trends toward personalized cancer care. The ability to stratify patients by recurrence risk could significantly impact treatment strategies and outcomes.

What we're watching

Clinical Adoption: How quickly Signatera's prognostic value will be integrated into standard adjuvant treatment decisions for lung cancer.
Market Expansion: Whether Natera can leverage this data to expand Signatera's use beyond lung cancer into other cancer types.
Reimbursement Dynamics: The pace at which payers will recognize and reimburse Signatera monitoring based on these findings.